Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (5y) (2017 - 2026)
Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.91% |
| Mar 31, 2026 | -16.15% |
| Dec 31, 2025 | 16.66% |
| Sep 30, 2025 | 0.33% |
| Jun 30, 2025 | -21.09% |
| Mar 31, 2025 | -20.39% |
| Dec 31, 2024 | 31.89% |
| Sep 30, 2024 | 15.26% |
| Jun 30, 2024 | -18.62% |
| Mar 31, 2024 | -5.70% |
| Dec 31, 2023 | -44.70% |
| Sep 30, 2023 | -19.70% |
| Jun 30, 2023 | 23.73% |
| Mar 31, 2023 | 96.73% |
| Dec 31, 2022 | -22.38% |
| Sep 30, 2022 | -18.48% |
| Jun 30, 2022 | -38.16% |
| Mar 31, 2022 | -110.45% |
| Dec 31, 2021 | 59.61% |
| Sep 30, 2021 | 53.08% |